

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

<b>BSE Limited</b> 1 <sup>st</sup> Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
<b>Kind Attn.:</b> Mr. Sanjay Golecha / Mr. Gopalkrishnan	<b>Kind Attn.:</b> Famroze Pochara Asst. Vice President
<b>Date:</b> July 19, 2017	
<b>Re.:</b> Press Release	

Dear Sir / Madam,


We enclose herewith a copy of press release dated July 19, 2017, titled "Zydus receives final approval from the USFDA for Tranexamic Acid Injection".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, Cadila Healthcare Limited



**Upen H. Shah**  
Company Secretary



Encl.: As above

## **Zydus receives final approval from the USFDA for Tranexamic Acid Injection**

---

*Ahmedabad, 19 July 2017*

Zydus Cadila has received the final approval from the USFDA to market Tranexamic Acid Injection, 1000 mg/10 mL (100 mg/mL) Single dose Vial. Tranexamic Acid Injection belongs to the class of medications called antifibrinolytic agents. This medication is used to prevent or reduce bleeding in patients with haemophilia undergoing tooth extraction and will be produced at the group's formulations manufacturing facility at Moraiya, in Ahmedabad.

The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

###